Positive results were announced from a phase 3b study comparing the investigational interleukin (IL)-17A and IL-17F inhibitor bimekizumab (UCB) to secukinumab, an IL-17A antagonist, for the treatment of adults with moderate to severe plaque psoriasis.

The double-blind, active comparator-controlled BE RADIANT study compared the efficacy and safety of bimekizumab to secukinumab in 743 adult patients with moderate to severe chronic plaque psoriasis for at least 6 months prior to screening, a baseline Psoriasis Area Severity Index (PASI) ≥12, an affected body surface area ≥10% and an Investigator’s Global Assessment (IGA) score ≥3. The study consisted of a 48-week double-blind treatment period and a 96-week open-label extension period. The primary end point was PASI 100 response (defined as a patient that achieved a 100% reduction from baseline in the PASI score) at week 16.

Results showed that treatment with bimekizumab was superior to secukinumab with regard to complete skin clearance (PASI 100 response) at week 16. Moreover, bimekizumab met all ranked secondary end points demonstrating superiority over secukinumab for PASI 75 at week 4 and PASI 100 at week 48. The safety profile of bimekizumab was observed to be consistent with that seen in previous studies. 

“The results mark the latest positive data readout for bimekizumab, confirming the hypothesis that targeting IL-17F, in addition to IL-17A, suppresses inflammation to a greater extent than IL-17A inhibition alone in psoriasis,” said Professor Richard Warren, Salford Royal NHS Foundation Trust and The University of Manchester, United Kingdom.

Related Articles

The bimekizumab clinical development program also includes the phase 3 BE VIVID, BE READY and BE SURE studies.

For more information visit ucb.com.


Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance. https://www.prnewswire.com/news-releases/bimekizumab-superior-to-cosentyx-in-achieving-complete-psoriasis-skin-clearance-301099229.html. Published 7/24/20. Accessed 7/27/20.